FDA advises pregnant women to avoid some migraine meds

05/6/2013 | USA Today · Hill, The

The FDA cautioned against the use of migraine treatment valproate sodium in pregnant women because it may lower the IQ score of the fetus. The agency cited recent research showing lower IQ scores in 6-year-old children who were exposed to such treatment while in the womb, compared with those who were exposed to other anti-seizure drugs. "Valproate medications should never be used in pregnant women for the prevention of migraine headaches because we have even more data now that show the risks to the children outweigh any treatment benefits for this use," said Russell Katz, director of the FDA's Division of Neurology Products.

View Full Article in:

USA Today · Hill, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD